Burlington, MA – According to filings with the U.S. Securities and Exchange Commission, Saliogen Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Raymond Tabibiazar played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Saliogen Therapeutics

SalioGen Therapeutics is advancing potentially curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived. SalioGen is initially focused on providing durable, safe and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.

To learn more about Saliogen Therapeutics, visit http://www.saliogen.com/

Contact:
Raymond Tabibiazar, Chief Executive Officer
650-906-9468
r.tabibiazar@saliogen.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved